Contineum Therapeutics, Inc.
We are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications – initially idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (progressive MS) with high unmet need. (Incorporated in […]
April 1, 2024 Read More